Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac

S. Kodoth; S. Bakshi; P. Scimeca; K. Black; S. Pahwa

doi:10.1089/108729101750301898

Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac

S. Kodoth, S. Bakshi, P. Scimeca, K. Black, S. Pahwa

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The use of protease Inhibitors (PI) has been associated with many adverse effects including increased tendency to bleed, which is particularly problematic in individuals with congenital coagulation disorders. We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving amprenavir (APV). The bleeding resolved on discontinuation of APV. This case report highlights a need for awareness of increased bleeding as a potentially serious complication associated with the use of all currently licensed PIs in individuals with hemophilia.

Original language	English (US)
Pages (from-to)	347-352
Number of pages	6
Journal	AIDS patient care and STDs
Volume	15
Issue number	7
DOIs	https://doi.org/10.1089/108729101750301898
State	Published - Jul 30 2001
Externally published	Yes

ASJC Scopus subject areas

Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1089/108729101750301898

Fingerprint Dive into the research topics of 'Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac'. Together they form a unique fingerprint.

Cite this

@article{ba67efec0a764f58a921a095bde38596,

title = "Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac",

abstract = "The use of protease Inhibitors (PI) has been associated with many adverse effects including increased tendency to bleed, which is particularly problematic in individuals with congenital coagulation disorders. We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving amprenavir (APV). The bleeding resolved on discontinuation of APV. This case report highlights a need for awareness of increased bleeding as a potentially serious complication associated with the use of all currently licensed PIs in individuals with hemophilia.",

author = "S. Kodoth and S. Bakshi and P. Scimeca and K. Black and S. Pahwa",

year = "2001",

month = jul,

day = "30",

doi = "10.1089/108729101750301898",

language = "English (US)",

volume = "15",

pages = "347--352",

journal = "AIDS Patient Care and STDs",

issn = "1087-2914",

publisher = "Mary Ann Liebert Inc.",

number = "7",

}

TY - JOUR

T1 - Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac

AU - Kodoth, S.

AU - Bakshi, S.

AU - Scimeca, P.

AU - Black, K.

AU - Pahwa, S.

PY - 2001/7/30

Y1 - 2001/7/30

N2 - The use of protease Inhibitors (PI) has been associated with many adverse effects including increased tendency to bleed, which is particularly problematic in individuals with congenital coagulation disorders. We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving amprenavir (APV). The bleeding resolved on discontinuation of APV. This case report highlights a need for awareness of increased bleeding as a potentially serious complication associated with the use of all currently licensed PIs in individuals with hemophilia.

AB - The use of protease Inhibitors (PI) has been associated with many adverse effects including increased tendency to bleed, which is particularly problematic in individuals with congenital coagulation disorders. We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving amprenavir (APV). The bleeding resolved on discontinuation of APV. This case report highlights a need for awareness of increased bleeding as a potentially serious complication associated with the use of all currently licensed PIs in individuals with hemophilia.

UR - http://www.scopus.com/inward/record.url?scp=0034945077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034945077&partnerID=8YFLogxK

U2 - 10.1089/108729101750301898

DO - 10.1089/108729101750301898

M3 - Article

C2 - 11483161

AN - SCOPUS:0034945077

VL - 15

SP - 347

EP - 352

JO - AIDS Patient Care and STDs

JF - AIDS Patient Care and STDs

SN - 1087-2914

IS - 7

ER -